Jesus D. Gonzalez-Lugo

Jesus D. Gonzalez-Lugo

Auto-generated profile, based on publicly available information

Jesus D. Gonzalez-Lugo

Division of Hemato-Oncology, Department of Oncology, Montefiore Einstein Cancer Center, Blood Cancer Institute, Bronx, New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JGJesus D. Gonzalez‐Lugo
Jesus D. Gonzalez‐Lugo
LBLizamarie Bachier‐Rodriguez
Lizamarie Bachier‐Rodriguez
MGMendel Goldfinger
Mendel Goldfinger
ASAditi Shastri
Aditi Shastri
RSR. Alejandro Sica
R. Alejandro Sica
IMIoannis Mantzaris
Ioannis Mantzaris
Monoclonal Gammopathy of Undetermined Significance (MGUS) is a pre‐malignant clonal plasma cell disorder, with 25 to 30% life‐long risk of progression to multiple myeloma (MM).1 It is usually asymptomatic, but infrequently associated with several serious conditions, such as neuropathies, glomerulonephritis, and acquired angioedema.2 Moreover, a higher risk of infection and deep venous thrombosis has been reported in patients with MGUS.3,4

18 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JGJesus D. Gonzalez-Lugo
Jesus D. Gonzalez-Lugo
SKSuman Kambhampati
Suman Kambhampati
AYAbdulraheem Yacoub
Abdulraheem Yacoub
WDWilliam B. Donnellan
William B. Donnellan
JBJesus Berdeja
Jesus Berdeja
Amit VermaAmit Verma
Amit Verma
Purpose: Thrombocytopenia is a serious complication of myelodysplastic syndromes (MDS) associated with an increased bleeding risk and worse prognosis. Eltrombopag (ELT), a thrombopoietin receptor agonist, can increase platelet counts and reverse anti-megakaryopoietic effects of lenalidomide (LEN) in preclinical studies. We hypothesized ELT would reduce the incidence of thrombocytopenia in MDS. Patients and Methods: We conducted a Phase II multicenter trial of ELT and LEN in adult patients with low- or intermediate-1–risk MDS with symptomatic or transfusion-dependent anemia or thrombocytopenia (NCT01772420). Thrombocytopenic patients were started on ELT and subsequently treated with LEN after platelets were increased. Patients without thrombocytopenia were started on LEN monotherapy and treated with ELT if they became thrombocytopenic. Results: Fifty-two patients were enrolled; mean age was 71 years (range 34–93). Overall response rate (ORR) in the intention-to-treat population was 35% (18/52). ELT monotherapy led to ORR of 33.3% (7/21), 29% achieving hematologic improvement (HI)-Platelets, and 24% bilineage responses. LEN monotherapy had 38% ORR (6/16) with all responders achieving HI-Erythroid. Fifteen patients received both ELT and LEN with ORR of 33.3%, 20% achieved HI-Erythroid, and 20% HI-Platelets with 13% bilineage responses. Median duration of response was 40 weeks for ELT (range 8–ongoing), 41 weeks (25–ongoing) for LEN, and 88 weeks (8.3–ongoing) for ELT/LEN. Non-hematologic grade 3–4 treatment-related adverse events were infrequent. Among patients on ELT, 2 had major bleeding events, 1 had a reversible increase in peripheral blasts, and 1 developed marrow fibrosis after 6 years on ELT. Conclusions: ELT and LEN are well tolerated and effective in achieving hematologic improvement in patients with low-/intermediate-risk MDS.

25 November 2025
Verified
Other
Open access
JGJesus D. Gonzalez-Lugo
Jesus D. Gonzalez-Lugo
SKSuman Kambhampati
Suman Kambhampati
AYAbdulraheem Yacoub
Abdulraheem Yacoub
WDWilliam B. Donnellan
William B. Donnellan
JBJesus Berdeja
Jesus Berdeja
Amit VermaAmit Verma
Amit Verma
Supplemental Table 1. MDS International Working Group response criteria for hematologic improvement Supplemental Table 2. Differences in Baseline Patient Characteristics Supplemental Table 3. Responses by Cytogenetics Supplemental Table 4. Responses by Mutation Supplemental Table 5. Study Representativeness Table

25 November 2025
Verified
Other
Open access
JGJesus D. Gonzalez-Lugo
Jesus D. Gonzalez-Lugo
SKSuman Kambhampati
Suman Kambhampati
AYAbdulraheem Yacoub
Abdulraheem Yacoub
WDWilliam B. Donnellan
William B. Donnellan
JBJesus Berdeja
Jesus Berdeja
Amit VermaAmit Verma
Amit Verma
Supplemental Figure 1. Overall Survival Responders vs Non-Responders Supplemental Figure 2. Overall Survival Among Groups

1 April 2023
Verified
Other
Open access
JGJesus D. Gonzalez-Lugo
Jesus D. Gonzalez-Lugo
SKSuman Kambhampati
Suman Kambhampati
AYAbdulraheem Yacoub
Abdulraheem Yacoub
WDWilliam B. Donnellan
William B. Donnellan
JBJesus Berdeja
Jesus Berdeja
Amit VermaAmit Verma
Amit Verma
Supplemental Table 1. MDS International Working Group response criteria for hematologic improvement Supplemental Table 2. Differences in Baseline Patient Characteristics Supplemental Table 3. Responses by Cytogenetics Supplemental Table 4. Responses by Mutation Supplemental Table 5. Study Representativeness Table

1 April 2023
Verified
Other
Open access
JGJesus D. Gonzalez-Lugo
Jesus D. Gonzalez-Lugo
SKSuman Kambhampati
Suman Kambhampati
AYAbdulraheem Yacoub
Abdulraheem Yacoub
WDWilliam B. Donnellan
William B. Donnellan
JBJesus Berdeja
Jesus Berdeja
Amit VermaAmit Verma
Amit Verma
Supplemental Figure 1. Overall Survival Responders vs Non-Responders Supplemental Figure 2. Overall Survival Among Groups